Dr. Anthony J Jaslowski, MD - Green Bay ...

Dr. Anthony J. Jaslowski

Claim this profile

Saint Vincent Hospital Cancer Center Green Bay

Studies Breast Cancer
Studies Cancer
27 reported clinical trials
49 drugs studied

Area of expertise

1Breast Cancer
Anthony J. Jaslowski has run 8 trials for Breast Cancer. Some of their research focus areas include:
HER2 positive
ER positive
ER negative
2Cancer
Anthony J. Jaslowski has run 7 trials for Cancer. Some of their research focus areas include:
Stage IV
KRAS positive
BRAF positive

Affiliated Hospitals

Image of trial facility.
Saint Vincent Hospital Cancer Center Green Bay
Image of trial facility.
Saint Vincent Hospital Cancer Center At Saint Mary's

Clinical Trials Anthony J. Jaslowski is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Cannabis Use

for Breast Cancer

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.
Recruiting1 award N/A10 criteria

More about Anthony J. Jaslowski

Clinical Trial Related6 years of experience running clinical trials · Led 27 trials as a Principal Investigator · 12 Active Clinical Trials
Treatments Anthony J. Jaslowski has experience with
  • Biospecimen Collection
  • Nivolumab
  • Questionnaire Administration
  • Paclitaxel
  • Pembrolizumab
  • Trastuzumab Emtansine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Anthony J. Jaslowski specialize in?
Is Anthony J. Jaslowski currently recruiting for clinical trials?
Are there any treatments that Anthony J. Jaslowski has studied deeply?
What is the best way to schedule an appointment with Anthony J. Jaslowski?
What is the office address of Anthony J. Jaslowski?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security